Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CA88024B1022
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01XVXG4M9
VIVI
TempraMed Technologies Ltd
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
TempraMed Technologies Ltd
ISIN
CA88024B1022
TICKER
VIVI
MIC
XCNQ
REUTERS
VIVI.CD
BLOOMBERG
VIVI CN
Fr., 18.09.2026       TempraMed
CA88024B1022

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 01.09.2026       TempraMed
CA88024B1022

Distribution framework pairs TempraMed's injectable medication-protection products with one of the largest, most established Greek pharmacy and healthcare distributorsHighlights:LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement.Proposed exclusivity is cond...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 25.08.2026       TempraMed
CA88024B1022

Agreement targets commercialization through the physical retail network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain.HighlightsFive-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order.Agreement covers a private-label versio...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Do., 20.08.2026       TempraMed
CA88024B1022

Maccabi exercises option to extend agreement for an additional year, reinforcing continued adoption of TempraMed's medication protection technologyToronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperat...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 18.08.2026       TempraMed
CA88024B1022

Agreement transitions previously announced LOI into a definitive commercial relationship First bulk commercial order fulfilled for distribution into clinics and pharmacies TempraMed expands access to its temperature-protection solutions through healthcare channels in PanamaToronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologie...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 04.08.2026       TempraMed
CA88024B1022

Integrates VIVI product portfolio into Stealth Health's rapidly expanding direct-to-patient telemedicine platform and enterprise white-label network, providing a solution to keep important medications safeVancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       TempraMed
CA88024B1022

Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have been approved to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares are also now DT...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Do., 09.07.2026       TempraMed
CA88024B1022

Acceptance of TempraMed's products by Meuhedet Health Services strengthens TempraMed's B2B institutional commercialization strategy as the Company advances reimbursement initiatives and expands relationships with leading healthcare organizations globallyHighlightsMeuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO)...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mo., 06.07.2026       TempraMed
CA88024B1022

HighlightsTempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir TradingKuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medicationsLOI includes minimum annual purchase commitments in Year 1Expands TempraMed's footprint across the Middle...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 30.06.2026       TempraMed
CA88024B1022

Integration into McKesson's Medical-Surgical Solutions marketplace serving a nationwide customer baseToronto, Ontario--(Newsfile Corp. - June 30, 2026) -  TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relati...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 26.06.2026       TempraMed
CA88024B1022

Strategic Saudi partnership with Rawafed Health International Company targets one of the region's largest diabetes and injectable-therapy markets, supported by leading healthcare infrastructure, pharmacy access in the regionToronto, Ontario--(Newsfile Corp. - June 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "C...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       TempraMed
CA88024B1022

Expands Latin America presence with strategic partnership with Mobil Saúde and builds on TempraMed's recently granted Brazilian patent portfolioHighlightsTempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world's largest markets for diabetes, GLP-1 therapies, and temperat...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2026       TempraMed
CA88024B1022

Broadcast across the United States brings attention to the under-addressed risk of medication degradation caused by heat exposure and the real-world need for better medication protection and trackingVancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a med...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Do., 14.05.2026       TempraMed
CA88024B1022

Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international marketsHighlightsGranted Patent covers the design of VIVI Cap Smart™ across major international, growing marketStrengthens the Company's intellectual property position in one of the world's largest healthcare and consumer...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has continued out of the provincial jurisdiction of British Colum...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       TempraMed
CA88024B1022

Grant in Brazil marks a major milestone in global IP strategy, advancing protection of its VIVI Box across key international marketsHighlightsBrazilian patent officially granted by the Brazilian Patent Office Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       TempraMed
CA88024B1022

Grant in China marks a major milestone in global IP strategy, advancing protection of its VIVI Box platform across key international marketsHighlightsChinese patent officially granted by CNIPA on March 17, 2026Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 11.03.2026       TempraMed
CA88024B1022

Peer-reviewed case report by Prof. Andreas Pfützner demonstrates real-world insulin protection during extreme heat exposure and aligns with previously validated savings modelVancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovat...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Do., 26.02.2026       TempraMed
CA88024B1022

Partnership results in over 275 physicians recommending VIVI Cap to patients, strengthening clinical validation and driving scalable patient education and acquisitionVancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator tr...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 10.02.2026       TempraMed
CA88024B1022

Super-Pharm operates nationwide, serving millions of consumers annuallyVancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Fr., 06.02.2026       TempraMed
CA88024B1022

Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured MembersVancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mo., 02.02.2026       TempraMed
CA88024B1022

Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed's full product portfolioVancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Fr., 23.01.2026       TempraMed
CA88024B1022

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channelsHighlightsUses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature med...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 14.01.2026       TempraMed
CA88024B1022

Validation is expected to accelerate TempraMed's path to payor reimbursement for product portfolioHighlightsROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibilityConfirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investmentSup...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered p...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 06.01.2026       TempraMed
CA88024B1022

Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activitiesVancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Fr., 02.01.2026       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 31.12.2025       TempraMed
CA88024B1022

Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected "VIVI Cap Smart" deviceVancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how tempe...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Fr., 26.12.2025       TempraMed
CA88024B1022

Integrated smart technology builds on TempraMed's proven VIVI platform, providing robust Temperature control with medication management for individuals using life-saving medicationHighlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every in...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 17.12.2025       TempraMed
CA88024B1022

New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B customers to address the forecasted increased demand for productsHighlights: Manufacturing site in Florida expands TempraMed's U.S. production footprintIncreases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device m...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mo., 15.12.2025       TempraMed
CA88024B1022

HighlightsNewly granted patent protects TempraMed's VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architectureExpands the Company's ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologicsEnhances commercialization opportunities and supports...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 10.12.2025       TempraMed
CA88024B1022

A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadershipVancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mo., 08.12.2025       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Fr., 05.12.2025       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a d...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 02.12.2025       TempraMed
CA88024B1022

Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products to gain tractionTurkey is one of the highest-prevalence diabetes countries in Europe due to obesity rates, diet, urbanization, and low screening complianceOne of many dist...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 26.11.2025       TempraMed
CA88024B1022

Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond and moreStrategic agreement supports TempraMed's global shift from online B2C to major pharmacy networks and B2B medical payersDistribution to over 2,500 outlets inclu...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 18.11.2025       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "9DY." The Company is also pleased to announce it has retained bullVes...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mo., 27.10.2025       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - October 27, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") the innovator behind the VIVI product line of temperature-protective solutions for injectable medications, is proud to announce its in-kind partnership of Beyond Type 1's 2025 TCS New York City Marathon...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 21.10.2025       TempraMed
CA88024B1022

Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of up to 3,289,473 units of the Company (each, a "Unit") at a price of C$0.76 per Unit for aggregate gross proceeds of up to C$2,...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 15.10.2025       TempraMed
CA88024B1022

Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of TempraMed Technologies Ltd. ("TempraMed" or the "Company"). The Company, based in Israel, recently completed a C$7.4 million private placement qualifying the issuance of approximately 51.7 million common s...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Mi., 15.10.2025       TempraMed
CA88024B1022

Announces Changes to the Board of DirectorsVancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange ("CSE"). Trading is ex...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink
Di., 14.10.2025       TempraMed
CA88024B1022

Toronto, Ontario--(Newsfile Corp. - Le 14 octobre/October 2025) - The common shares of TempraMed Technologies Ltd. have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date. TempraMed develops patent-protected technology designed to serve a br...
Zur Nachricht
TempraMed
Charts & Research Termsheets Terminal
Permalink